Gestiva Passes Cmte. Review, But Further Study Of Miscarriage Risk Requested

FDA’s Reproductive Health Advisory Committee votes that safety and efficacy of Adeza’s preterm birth agent Gestiva have been demonstrated.

More from Archive

More from Pink Sheet